Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients
Background/Aims: In a randomized controlled clinical trial in kidney transplant recipients (NCT01377467) we have recently shown that RANKL inhibition with denosumab significantly improved areal bone mineral density (aBMD) when given during the first year after transplantation. The effect of denosuma...
Main Authors: | Marco Bonani, Ursina Meyer, Diana Frey, Nicole Graf, Heike A. Bischoff-Ferrari, Rudolf P. Wüthrich |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2016-09-01
|
Series: | Kidney & Blood Pressure Research |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/447930 |
Similar Items
-
Association between radiographic hand osteoarthritis and bone microarchitecture in a population-based sample
by: Canchen Ma, et al.
Published: (2022-09-01) -
Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab
by: Claudia Kobel, et al.
Published: (2019-10-01) -
Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial
by: Demostenis Kiritopoulos, et al.
Published: (2022-09-01) -
Denosumab treatment in patients with different courses of osteoporosis
by: Liudmila Ya. Rozhinskaya, et al.
Published: (2017-12-01) -
The Benefits to Bone Health in Children and Pre-School Children with Additional Exercise Interventions: A Systematic Review and Meta-Analysis
by: Callum McCaskie, et al.
Published: (2022-12-01)